Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer

Condition:   Breast Neoplasms Interventions:   Drug: Denosumab 120 mg;   Drug: Denosumab 60 mg Sponsors:   Borstkanker Onderzoek Groep;   Amgen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials